Hereditary Leiomyomatosis and Renal Cell Cancer Clinical Trial
Official title:
Randomized Pilot Study for the Treatment of Cutaneous Leiomyomas With Botulinum Toxin
Cutaneous leiomyomas are benign tumors of smooth muscle origin. They can be very painful,
and current treatments for the tumors and for the associated pain do not produce
satisfactory results. One potential treatment for localized severe muscle pain involves
injections with botulinum toxin A. This study will investigate the effectiveness, side
effects, and dosage of botulinum toxin A (BOTOX) as a treatment for patients with pain
associated with cutaneous leiomyomas.
This study will include 18 subjects, all of whom will be 18 years of age and older, who have
pain associated with cutaneous leiomyomas.
For the 24-week study, patients will be randomly assigned to one of two treatment groups.
Neither the study team nor the patient will know to which group patients have been assigned.
Before the study begins, all participants must provide a full medical history for research
and evaluation purposes, fill out pain and quality-of-life questionnaires, and undergo an
ice test in which researchers will apply ice to the site of the cutaneous leiomyomas and ask
participants to evaluate the level of pain before and after ice application. Both groups
will be required to keep a pain diary throughout the study to record their level of pain on
a daily basis, and will be asked to avoid or restrict the use of specific medications or
other remedies to treat the pain.
At the first visit (Week 0), one group will receive a prescribed dose of botulinum toxin A,
which will be administered as an injection into the leiomyoma, and the other (control) group
will receive a placebo injection of a saline solution. Patients will return 4 weeks later,
at which time they will undergo a medical examination, and the ice test, and complete
questionnaires to assess responses and level of pain. Patients will return in Week 12, at
which time the group assignment will be revealed (un-blinded) to investigators and patients.
Patients who received placebo injections will be offered the opportunity to receive
injection of botulinum toxin A into their leiomyomas. All patients will undergo a medical
examination, the ice test, complete questionnaires, and continue completing their daily pain
diaries at home. The final visit, in Week 24, will follow the same procedure as the Week 4
visit.
At the end of the study, patients may be eligible to have one or more of the painful
cutaneous leiomyomas surgically removed if the researchers believe that the skin lesions can
be removed with a reasonable cosmetic result.
| Status | Completed |
| Enrollment | 18 |
| Est. completion date | February 2015 |
| Est. primary completion date | March 2014 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 18 Years and older |
| Eligibility |
- INCLUSION CRITERIA: 1. Subjects must be age greater than or equal to18 years. 2. Subjects must have a prior biopsy-proven diagnosis of cutaneous leiomyoma. 3. Subjects must have at least 1 symptomatic leiomyomas or regions less than or equal to 60 cm^2 of leiomyomas with pain characterized as greater than 4 based on a 10-point scale, indicating pain of at least moderate severity. 4. Pain episodes must occur at least once a week. 5. Subjects must have the ability to participate fully and comply with the procedures of the protocol in the opinion of the investigator. 6. Written informed consent has been obtained including consenting to have tissue samples stored, however subjects are allowed to refuse sample storage. 7. Negative urine or serum pregnancy test in females of childbearing potential. 8. Subjects who are clinically stable such that they can be expected to complete the 24-week study. EXCLUSION CRITERIA: 1. Subjects with allergies to BTX-A. 2. Females with a positive pregnancy test, or who are breast-feeding, planning a pregnancy during the study, who think that they may be pregnant at the start of the study or females of childbearing potential who are unable or unwilling to use a reliable form of contraception during the study. 3. Subjects with neuromuscular junction disorders (ie. myasthenia gravis or Lambert-Eaton syndrome) or peripheral motor neuropathic diseases (ie. amyotrophic lateral sclerosis or motor neuropathy). 4. Subjects with infection at the intended sites of injection. 5. Subjects who have had prior Botulinum toxin product within the past 6 months. 6. Subjects with pain resulting from other disease(s), specifically: - pain that requires intermittent or ongoing treatment with narcotics - severe, debilitating, or acute pain originating from sources other than leiomyomas 7. Subjects taking pain medications, neuroactive agents, or other therapy directed toward treatment of cutaneous leiomyomas concurrently or within 5 days or 5 half-lives (whichever is longer) of BTX-A treatment, other than specified rescue pain medications). Patients currently on therapy directed toward OTHER mild to moderate chronic pain will be evaluated on a case-by-case basis for inclusion. Patients with well-controlled mild to moderate chronic pain such as that associated with osteoarthritis, who do not require narcotic therapy, will NOT be excluded. Aspirin for pain relief or for other indications is also acceptable. 8. Subjects with late-stage cancers or unstable disease (such as hemodynamic instability, i.e., systolic or diastolic blood pressure fall of 20 mm Hg or greater from the stable patient s baseline measurement). 9. A condition or situation that, in the investigator's opinion, may put the subject at significant risk or interfere significantly with the subject's participation in the study. |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| United States | National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda | Maryland |
| Lead Sponsor | Collaborator |
|---|---|
| National Cancer Institute (NCI) |
United States,
Archer CB, Whittaker S, Greaves MW. Pharmacological modulation of cold-induced pain in cutaneous leiomyomata. Br J Dermatol. 1988 Feb;118(2):255-60. — View Citation
Batchelor RJ, Lyon CC, Highet AS. Successful treatment of pain in two patients with cutaneous leiomyomata with the oral alpha-1 adrenoceptor antagonist, doxazosin. Br J Dermatol. 2004 Apr;150(4):775-6. — View Citation
Naik HB, Steinberg SM, Middelton LA, Hewitt SM, Zuo RC, Linehan WM, Kong HH, Cowen EW. Efficacy of Intralesional Botulinum Toxin A for Treatment of Painful Cutaneous Leiomyomas: A Randomized Clinical Trial. JAMA Dermatol. 2015 Oct;151(10):1096-102. doi: 1 — View Citation
Raj S, Calonje E, Kraus M, Kavanagh G, Newman PL, Fletcher CD. Cutaneous pilar leiomyoma: clinicopathologic analysis of 53 lesions in 45 patients. Am J Dermatopathol. 1997 Feb;19(1):2-9. — View Citation
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Change in Worst Lesional Pain in the Past Week Based on Brief Pain Inventory | Change in worst lesional pain in the past week based on Brief Pain Inventory (BPI) from Week 0 to Week 4 in treated patients versus controls. The BPI uses an arbitrary units on a 0-10 scale. For the purposes of the statistical calculation, a difference of 1 standard deviation between groups at baseline vs. week 4 was considered significant. Any BPI value above zero (no pain) is abnormal. The mean change indicates mean change in pain score. | Up to 4 weeks | No |
| Secondary | Number of Participants With Adverse Events | Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module. | 37 months | Yes |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04623502 -
An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy
|
N/A | |
| Recruiting |
NCT03749980 -
MyVHL: Patient Natural History Study
|